BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1146 related articles for article (PubMed ID: 34691027)

  • 1. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease.
    Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T
    Front Immunol; 2021; 12():719807. PubMed ID: 34691027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
    Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
    J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Echinacoside exerts neuroprotection via suppressing microglial α-synuclein/TLR2/NF-κB/NLRP3 axis in parkinsonian models.
    Yang XP; Huang JH; Ye FL; Yv QY; Chen S; Li WW; Zhu M
    Phytomedicine; 2024 Jan; 123():155230. PubMed ID: 38000105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.
    Soraci L; Gambuzza ME; Biscetti L; Laganà P; Lo Russo C; Buda A; Barresi G; Corsonello A; Lattanzio F; Lorello G; Filippelli G; Marino S
    J Neurol; 2023 Mar; 270(3):1346-1360. PubMed ID: 36460875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The circadian clock protein Rev-erbα provides neuroprotection and attenuates neuroinflammation against Parkinson's disease via the microglial NLRP3 inflammasome.
    Kou L; Chi X; Sun Y; Han C; Wan F; Hu J; Yin S; Wu J; Li Y; Zhou Q; Zou W; Xiong N; Huang J; Xia Y; Wang T
    J Neuroinflammation; 2022 Jun; 19(1):133. PubMed ID: 35668454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment.
    Que R; Zheng J; Chang Z; Zhang W; Li H; Xie Z; Huang Z; Wang HT; Xu J; Jin D; Yang W; Tan EK; Wang Q
    Front Immunol; 2021; 12():794770. PubMed ID: 34925379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia.
    Panicker N; Sarkar S; Harischandra DS; Neal M; Kam TI; Jin H; Saminathan H; Langley M; Charli A; Samidurai M; Rokad D; Ghaisas S; Pletnikova O; Dawson VL; Dawson TM; Anantharam V; Kanthasamy AG; Kanthasamy A
    J Exp Med; 2019 Jun; 216(6):1411-1430. PubMed ID: 31036561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.
    Zhou Y; Lu M; Du RH; Qiao C; Jiang CY; Zhang KZ; Ding JH; Hu G
    Mol Neurodegener; 2016 Apr; 11():28. PubMed ID: 27084336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease.
    Pike AF; Longhena F; Faustini G; van Eik JM; Gombert I; Herrebout MAC; Fayed MMHE; Sandre M; Varanita T; Teunissen CE; Hoozemans JJM; Bellucci A; Veerhuis R; Bubacco L
    J Neuroinflammation; 2022 Feb; 19(1):50. PubMed ID: 35172843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.
    Gordon R; Albornoz EA; Christie DC; Langley MR; Kumar V; Mantovani S; Robertson AAB; Butler MS; Rowe DB; O'Neill LA; Kanthasamy AG; Schroder K; Cooper MA; Woodruff TM
    Sci Transl Med; 2018 Oct; 10(465):. PubMed ID: 30381407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TREM2 Deficiency Aggravates NLRP3 Inflammasome Activation and Pyroptosis in MPTP-Induced Parkinson's Disease Mice and LPS-Induced BV2 Cells.
    Huang P; Zhang Z; Zhang P; Feng J; Xie J; Zheng Y; Liang X; Zhu B; Chen Z; Feng S; Wang L; Lu J; Liu Y; Zhang Y
    Mol Neurobiol; 2024 May; 61(5):2590-2605. PubMed ID: 37917301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease.
    Grotemeyer A; Fischer JF; Koprich JB; Brotchie JM; Blum R; Volkmann J; Ip CW
    J Neuroinflammation; 2023 Mar; 20(1):79. PubMed ID: 36945016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p38-TFEB pathways promote microglia activation through inhibiting CMA-mediated NLRP3 degradation in Parkinson's disease.
    Chen J; Mao K; Yu H; Wen Y; She H; Zhang H; Liu L; Li M; Li W; Zou F
    J Neuroinflammation; 2021 Dec; 18(1):295. PubMed ID: 34930303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of α-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson's disease.
    Lv QK; Tao KX; Wang XB; Yao XY; Pang MZ; Liu JY; Wang F; Liu CF
    Inflamm Res; 2023 Mar; 72(3):443-462. PubMed ID: 36598534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay between α-Synuclein and NLRP3 inflammasome in Parkinson's disease.
    Huang Q; Yang P; Liu Y; Ding J; Lu M; Hu G
    Biomed Pharmacother; 2023 Dec; 168():115735. PubMed ID: 37852103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein evokes NLRP3 inflammasome-mediated IL-1β secretion from primary human microglia.
    Pike AF; Varanita T; Herrebout MAC; Plug BC; Kole J; Musters RJP; Teunissen CE; Hoozemans JJM; Bubacco L; Veerhuis R
    Glia; 2021 Jun; 69(6):1413-1428. PubMed ID: 33506583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities.
    Çınar E; Tel BC; Şahin G
    Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Haque ME; Akther M; Jakaria M; Kim IS; Azam S; Choi DK
    Mov Disord; 2020 Jan; 35(1):20-33. PubMed ID: 31680318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation.
    Chen CM; Yen CY; Chen WL; Lin CH; Wu YR; Chang KH; Lee-Chen GJ
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baohuoside I suppresses the NLRP3 inflammasome activation via targeting GPER to fight against Parkinson's disease.
    Gu Y; Hu ZF; Zheng DW; Yang YQ; Dong XL; Chen WF
    Phytomedicine; 2024 Apr; 126():155435. PubMed ID: 38394727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.